20170629 Servier Transgene EN
Category: Press release
Transgene Hosts Immuno-Oncology R&D Day Focused on Modulating the Tumor Micro-Environment in Paris
20170622 CP RD Day EN
Combined General Meeting of June 8, 2017
20170608 TG AGM June 2017 EN
€50.7 Million in Cash and Cash Equivalents as of March 31, 2017
20170425 PR Q1-2017
Transgene and Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate TG4010 in Combination with Opdivo and Standard Chemotherapy in First Line Non-Small Cell Lung Cancer
20170425 BMS-Clinical Collaboration Release Transgene-FINAL
SillaJen and Transgene Announce the Enrollment of the First European Patient in Multinational Phase 3 Trial for Pexa-Vec in Advanced Liver Cancer
20170424 PR PHOCUS FPI EU – EN
Marie Landel and Maya Said Nominated to be Independent Members of Transgene’s Board of Directors
20170419 TG Appointments Board EN
Transgene and Institut Bergonié Start the Phase 2 Part of the METROmaJX Trial
20170412 PR Metro-JX Ph2 EN
Transgene Announces Upcoming Investor Meetings and R&D Day
20170410 PR Next investor events
Transgene Presents Very Promising New Immunology Data of its Next Generation Armed Oncolytic Virus at the AACR Annual Meeting in Washington, DC
20170330-AACR poster EN